|
LONDON STOCK EXCHANGE
AstraZeneca
a été créé le 9 avril 1999 par la fusion du
laboratoire suédois Astra et du laboratoire britannique Zeneca.
AstraZeneca est l'un des premiers laboratoires pharmaceutiques au monde.
Particulièrement
engagée dans la recherche, notre société possède
une large gamme de produits conçus pour lutter contre
la
maladie là où les besoins médicaux sont les plus importants.
AstraZeneca
est présent dans sept domaines thérapeutiques majeurs : l'anesthésiologie,
la cardiologie, l'infectiologie, la gastro-entérologie, l'oncologie,
la neurologie, la pneumologie.
PHASE
III Study Compares Vandetanib (Zactima(TM), ZD6474) to Erlotinib in Advanced
Lung Cancer PRNewswire - ALDERLEY PARK, England September 28 -
ALDERLEY
PARK, England, September 28 /PRNewswire/ --
-
First Patient Enrolled in Pivotal International Randomised, Double-Blind
Study of Vandetanib Versus Erlotinib
FOR
NON-US HEALTHCARE PROFESSIONAL PRESS ONLY
AstraZeneca
(NYSE:AZN) today announced the start of enrolment into a new Phase III
study of the novel once-daily oral anti-cancer drug, vandetanib (ZACTIMA(TM),
ZD6474), comparing it with erlotinib in patients with locally advanced
or metastatic non-small cell lung cancer (NSCLC).
The
study, known as Study 57, will be conducted at approximately 160 centres
across 23 countries, and is expected to enrol over 1,150 patients. It marks
the first Phase III direct comparison of vandetanib with erlotinib, and
forms part of an extensive clinical development programme of vandetanib
in NSCLC.
Over
1.35 million new cases of lung cancer are diagnosed every year and nearly
1.2 million people die as a result of this devastating disease - more than
breast, colon and prostate cancer combined.(1) Study 57 will evaluate progression
free survival with oral vandetanib 300mg compared with oral erlotinib 150mg
in patients with advanced NSCLC after failure of at least one but no more
than two prior chemotherapy regimens. The study will also compare vandetanib
and erlotinib for overall survival, objective response rate, disease control
rate, response duration, effect on disease related symptoms, quality of
life assessments, and safety and tolerability.
Medical
Science Director for ZACTIMA at AstraZeneca, Peter Langmuir, commented,
"Research in lung cancer has helped us identify specific pathways that
play an important role in the development and progression of this disease.
Treatments are in development that reflect these research advances, and
investigation is needed to assess anti-tumour activity with new agents
which target multiple key pathways, such as vandetanib, compared to currently
available single-target treatments."
Study
57 is the second Phase III study for vandetanib in NSCLC to have begun
patient enrolment this year. Study 32, announced in June 2006, is an international
randomised, double-blind, placebo controlled study, comparing treatment
with vandetanib 100mg plus docetaxel versus docetaxel alone in patients
with locally advanced or metastatic NSCLC after failure of first-line treatment.
Vandetanib
(ZACTIMA(TM), ZD6474)
Vandetanib
works by inhibiting both the development of the tumour's blood supply through
inhibition of VEGFR (anti-angiogenesis) and the growth and survival of
the tumour itself through inhibition of EGFR. It also inhibits RET kinase,
an important growth factor in certain types of thyroid cancer. Vandetanib
has shown promising anti-tumour activity in NSCLCwhen used alone and in
combination with docetaxel in Phase II trials.(2,3) Vandetanib has also
shown encouraging early data in hereditary medullary thyroid cancer(4)
and has been awarded FDA and EU orphan drug status, and FDA fast track
designation for this indication. Vandetanib is currently in clinical development
in a range of tumours.
ZACTIMA(TM)
is a trademark of the AstraZeneca group of companies.
Notes
to editors
-
Lung cancer is a leading cause of cancer death for both men and women worldwide
and the incidence is increasing.(1) Prognosis for lung cancer is generally
poor. If lung cancer is detected at early stages, before it has spread
to other organs or lymph nodes, around half of patients can survive for
five years or more. However, few lung cancers are found at thisearly stage
and it is normally diagnosed at the advanced stage, when five year survival
falls to approximately 15%.(5) - AstraZeneca is a major international healthcare
business engaged in the research, development, manufacture and marketing
of prescription pharmaceuticals and the supply of healthcare
services.
It is one of the world's leading pharmaceutical companies with healthcare
sales of US$23.95 billion and leading positions in sales of gastrointestinal,
cardiovascular, neuroscience, respiratory, oncology and infection products.
AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as
well as the FTSE4Good Index.
-
For more information about AstraZeneca, please visit: www.astrazeneca.com
For
further information, please contact:
Janet
Milton-Edwards Carrie Deverell AstraZeneca AstraZeneca Tel: +44-(0)-1625-515-275
Tel: +44-(0)-1625-514-77 Mobile: +44-(0)-7990-640-119 Mobile:
+44-(0)-7929-845-108
janet.milton-edwards@astrazeneca.com carrie.deverell@astrazeneca.com
ALDERLEY
PARK, England, September 28 /PRNewswire/ --
References
1.
Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality
and Prevalence Worldwide IARC CancerBase No. 5. version 2.0, IARCPress,
Lyon, 2004.
2.
Natale R et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib
(Iressa(TM)) in patients with NSCLC: results of a randomized, double-blind
Phase II study. Lung
Cancer
2005; 49 (Suppl 2): S36.
3.
Herbst R et al. ZD6474 plus docetaxel in patients with previously treated
NSCLC: results of a randomized, placebo-controlled phase II trial. Lung
Cancer 2005; 49 (Suppl 2): S35.
4.
Wells S et al. The Use of ZACTIMA(TM) (ZD6474) in the Treatment of Patients
with Hereditary Medullary Thyroid Carcinoma. Presented at the AACR-NCI-EORTC
International
Conference on Molecular Targets and Cancer Therapeutics, November 2005.
5.
Bepler G. Lung cancer epidemiology and genetics. Journal of Thoracic Imaging
1999;14(4):228-34.
AstraZeneca
-
Janet
Milton-Edwards, AstraZeneca, Tel: +44-(0)-1625-515-275, Mobile: +44-(0)-7990-640-119,
janet.milton-edwards@astrazeneca.com, Carrie Deverell, AstraZeneca, Tel:
+44-(0)-1625-514-77,
Mobile: +44-(0)-7929-845-108, carrie.deverell@astrazeneca.com |
